Lenalidomide Reduces Risk of Progression in High Risk Smoldering Myeloma
St. Louis Round Table - May 18, 2019
Off-the Shelf CAR T Cell Therapy Targeting CS1 by Cellectis with David Siegel, MD, PhD, Hackensack University
Learn more about this fascinating new approach to CAR T therapy from Dr. David Siegel, a leading myeloma researcher at Hackensack University.
New Discovery in the Prevention of Kidney Disease in Multiple Myeloma Patients
Just Breathe: Sleep Apnea and Multiple Myeloma and the Role of Oxygen Therapy after Transplant
Medicare Coverage - Is It Enough for Multiple Myeloma CAR T Therapies?
Melphalan and High Dose IV Vitamin C for Multiple Myeloma with Yogesh Jethava, MD, University of Iowa
Dr. Jethava shares how his open clinical trial for relapsed or refractory myeloma patients can use low doses of melphalan combined with high dose IV Vitamin C
Busulfan Plus Melphalan: A Promising Combination For Auto-Stem Cell Transplant in Multiple Myeloma
What Is Chemo Brain?
Potential Future Product to Lower the Cost of Multiple Myeloma Treatment
Kappa or Lambda Myeloma Testing. Is there a Difference?
Blood Changes After Pesticide Exposure in Multiple Myeloma
Clinical Trial: Reducing Insomnia of Cancer Survivors with Yoga vs. Health Education and Cognitive Behavioral Therapy
HealthTree for Multiple Myeloma Featured on the Today Show
New HDAC Inhibitor for Multiple Myeloma In Early Chinese Study
Using the New Treatment Combo for Multiple Myeloma (Elotuzumab Pomalidomide and Dex) in the Clinic
Myeloma Awareness Month: How to Find a Myeloma Specialist
Patient Power: Exercising with Shortness of Breath
Being Minimal Residual Disease Negative Before or After Transplant Means Better Overall Survival for Myeloma Patients
Multiple Myeloma Questions & Answers
Myeloma Awareness Month: What Patients Need to Know to Improve Their Myeloma Survival
How to Pay For Your Myeloma Treatment? (Part II: When You Have Private Insurance Or No Insurance)
A New CD38 Monocloncal Antibody Called Isatuximab Gets Closer to the Clinic, with Ravi Vij, MD, Washington University
A new CD38 targeted monoclonal antibody is coming soon to the myeloma clinic. A new drug called isatuximab is making its way through the FDA approval process.
How to Pay for Your Myeloma Treatment??
